David Aggen, MD

We didn’t get to highlight two important trials for metastatic UC with pure variant histologic features nearly enough.

🔹 ICONIC (nivo/ipi/cabo): clinicaltrials.gov/study/NCT038...
🔹 EV + Pembro IIT (Emory): www.clinicaltrials.gov/study/NCT057...

Episode 472: Uromigos Shorts - Variant Histology Bladder Cancer Episodio de podcast · The Uromigos · 12/01/2026 · 27 min

Really enjoyed talking with the original Uromigos Brian Rini & Tom Powles about variant histology bladder cancer.

🎧 Uromigos Episode 472 — podcasts.apple.com/es/podcast/e...

worth a listen
#BladderCancer

Variant histologies in bladder cancer are like different genres of music

Same stage - different openers and headliners

Watch here ➡️ x.com/uromigos/sta...

Think of them as music genres—same stage, different openers (neoadj.) and headliners (1st line tx).

🎤 From micropapillary to plasmacytoid—each has a style & strategy.

Uromigos on X: "The UromigosLive 2025 meeting presents #UromigosShorts videos on GU Oncology topics. The videos with the most views win a prize at #UromigosLive November 7-8th in Nashville, TN. Below, Dr. David Aggen discusses : Variant Histology Bladder Cancer. https://t.co/h3DFbgnz3G" / X The UromigosLive 2025 meeting presents #UromigosShorts videos on GU Oncology topics. The videos with the most views win a prize at #UromigosLive November 7-8th in Nashville, TN. Below, Dr. David Aggen discusses : Variant Histology Bladder Cancer. https://t.co/h3DFbgnz3G

🎶 Wondering how to tackle variant histologies in bladder cancer?

🎧 Watch here ⬇️

x.com/uromigos/sta...

@Uromigos @Dr_Aggen @BladderCancerUS
#BladderCancer #UroOnc #GUonc #PathTwitter

If you are looking for updates in #GU, join us in NYC on 4/30 for @OncLive #Stateofthescience summit. Free for healthcare professionals to register here!

shorturl.at/uTCUA

Very proud of rising star fellow Aditi Gupta for her work on immune profiling in mUC patients receiving EV #ASCOGU @MSKCancerCenter #GU25

Fantastic to see @IyerGopa showing updated data from FGFR3 inhibitor Loxo-435 with

ORR of 41%
DCR 90%
50% (6/12 patients) confirmed responses with prior FGFR3 inhibitor

@MSKCancerCenter #ASCOGU #GU25

Excited to hear a review of the DV + PD-1 from our MSK Cancer Center colleague Scot Niglio #ASCOGU #GU25

Path Cr rate of 84.6% in HER2 3+

#MattMilowsky with updated #Checkmate274 trial - adjuvant nivolumab after cystectomy improves time to recurrence & overall survival in #bladdercancer. Sets up ongoing #Alliance #MODERN trial! @ascocancer.bsky.social #GU25

Memorial Sloan Kettering Cancer Center Surgeon-Scientist, Vinod Balachandran, MD, Named to The Washington Post Next 50 Memorial Sloan Kettering Cancer Center (MSK) is pleased to announce The Washington Post has named Vinod Balachandran, MD, surgeon-scientist and Director of The Olayan Center for Cancer Vaccines at MSK...

Congrats to Vinod Balachandran, a surgeon-scientist and Director of The Olayan Center for Cancer Vaccines at MSK, for being named to the inaugural edition of the @washingtonpost's Next 50, a list of up-and-coming changemakers shaping society in 2025.

bit.ly/3CMJhN6

Our paper in @nature.com is finally published: a prospective trial of a personalized Neoantigen Vaccine in Kidney Cancer

www.nature.com/articles/s41...

This is teamwork with @danafarber.bsky.social @yalecancer.bsky.social @harvardmed.bsky.social + Wu lab

www.nature.com/articles/s41...

Opinion | I’m a health researcher. NIH’s pause on research grants could have a devastating cost. This is a potentially devastating event — not just for the scientific community, but for all Americans.

An explainer about how health research funding happens and why this NIH funding cycle shutdown matters: www.msnbc.com/opinion/msnb...

Gopa Iyer discussing the potential for platinum following EV + pembro for advanced UC #AUC3 #bladdercancer

This GU oncology family — wonderful first #AUC3 consensus conference!
@drchoueiri.bsky.social @pgrivasmdphd.bsky.social @davidaggen.bsky.social

At #AUC3 this A.M. discussing what’s next for treatment of NMIBC and treatment of variant histology UC - Gopa Iyer and Josh Meeks chairing session this AM with talks from Andrea Necchi, Michiel Van der Heijden, and Roger Li #bladdercancer

Dr. Marie Carlo discussing the role of NGS and germline testing for RCC and non-clear cell RCC @MSKCancerCenter #auc3 #kidneycancer @BradMcG04 chairing session

Dr. Motzer reviewing the treatment landscape for advanced kidney cancer. Discussing when is the right time to introduce belzutifan. @MSKCancerCenter #AUC3 #kidneycancer

Stellar overview of cytoreductive nephrectomy in the era of combination immunotherapy by Ari Hakimi #auc3 #kidneycancer

Next-Generation Sequencing for HLA Genotype Screening and Matching to HLA-Restricted Therapies This case series evaluates whether human leukocyte antigen (HLA) genotype could be inferred from standard next-generation sequencing, comparing concordance with confirmatory whole-exome sequencing and...

As we explore more and more HLA-specific immune based therapies, this from MSK in JAMA Onc shows that standard NGS testing can infer HLA genotypes. Other NGS providers have done/can do @adamjschoenfeld.bsky.social @mskcancercenter.bsky.social @davidaggen.bsky.social jamanetwork.com/journals/jam...

U.S. Surgeon General Calls for Cancer Warnings on Alcohol Dr. Vivek Murthy’s report cites studies linking alcoholic beverages to at least seven malignancies, including breast cancer. But to add warning labels, Congress would have to act.

Surgeon General Calls for Cancer Warnings on Alcohol www.nytimes.com/2025/01/03/h... I think American Cancer Society and @ascocancer.bsky.social @jrgralow.bsky.social should support this initiative @oncoalert.bsky.social

Innovative Therapies in GU Cancers: Promising Targets in Urothelial and Kidney Cancer - Jonathan Rosenberg Alicia Morgans speaks with Jonathan Rosenberg about two novel therapies presented at ESMO 2024. The discussion centers on BL-B01D1, a bispecific antibody-drug conjugate targeting EGFR and HER3 in adva...

Innovative therapies in GU cancers: Promising targets in #Urothelial and #Kidney cancer.- BL-B01D1: A bispecific ADC (EGFR/HER3) with a 40% response rate in advanced urothelial cancer.
- NKT2152: A HIF2a inhibitor for RCC, showing promise but with toxicity challenges > bit.ly/3OUcvfe

I just helped save a life You can save one, too. Donate now.

My heart sank when I heard the news that Felix Feng has passed away. Felix was such a gentle and uplifting force for so many of us who work in the same field - and for anyone he touched. Although he has left us, his impact will be felt forever. ow.ly/Uc3H50TSBiC

Rich Matulewicz #SUO24

“Blockbuster New Therapy for Cancer…. Smoking Cessation “.

@joshmeeks.bsky.social
@yawnyame.bsky.social
@wandering-gu.bsky.social

#SUO24 Implementing Smoking Cessation in the Urologic Oncology Setting @RichMatulewicz

Urologists: the most trusted and utilized source of information regarding the cause and 🚬-related nature of the patient’s bladder ca diagnosis

@urotoday

@RichMatulewicz representing @UrologyMSK at the #SUO24 discussing clinical evolution in the management of seminoma.

AI has a huge potential in #BladderCancer for diagnosis, prognostic and predictive assessment
Some questions remain to be answered related to:
▶️ Heterogeneity of disease
▶️ Interreader variability of pathology assessment
▶️ Which ground truth to apply? #AI #MachineLearning @oncoalert.bsky.social

We are excited to enroll patients with LN + bladder cancer on our neoadjuvant enfortumab vedotin + pembrolizumab trial @mskcc.bsky.sm

Now enrolling patients with N1-N3 disease #BLCSM

6 Cycles EV + P -> Cystectomy -> Pembrolizumab

www.mskcc.org/cancer-care/...

We are actively enrolling patients with high risk bladder cancer on a trial evaluating a personalized mRNA neoantigen vaccine following bladder surgery. @mskcc.bsky.social #blcsm #bladdercancer www.mskcc.org/cancer-care/...